Health
Hope grows for blood cancer patients, as cell therapy firm’s key trial succeeds – The Times of Israel
Gamida Cell shares surge after results of key trial show flagship drug results in faster blood count recovery, fewer bacterial and viral infections after bone marrow…
Gamida Cell Ltd., a maker of cell and immune therapy technologies, on Wednesday published the results of a key late-stage clinical trial of its flagship drug, which aims to increase the success of bone marrow transplants in blood cancer patients — triggering a surge in its Nasdaq-traded shares.
Gamida’s shares jumped almost 26% on the US exchange Wednesday. The shares have advanced 163% in the past 12 months, leading to a company valuation of $733 million. The firm held its initial public offering…
-
Noosa News19 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News17 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News18 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News18 hours agoGood character references restricted in rape cases in Queensland